Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

APRIL 14, 2022

Before legalization, illicit grow sites did not have access to water utilities and were typically grown in arid/remote areas, often depleting local surface water and shallow aquifers not suited to intensive use. Indoor grow operations also can create a significant new demand on utility water supply infrastructure. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

APRIL 21, 2022

and Canada highlights mounting cases of cannabis poisoning among pets and sheds new light on symptoms, treatments, and outcomes. Richard Quansah Amissah of the Ontario Veterinary College at the University of Guelph in Ontario, Canada, and colleagues present these findings in the open-access journal PLOS ONE on April 20, 2022.

Pets 52

Pets Research and Development Topical Consumption 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JANUARY 21, 2022

Supreme Court to hear her appeal over coverage of medical marijuana treatments, as reported in the article “ U.S. Full access to the complete content of Best’s Review is available here. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Best Company, Inc.

Treatment 52

Treatment Data Business Access 52

Cannabis Law Report

JUNE 8, 2022

Published: Jun 07, 2022. Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access. MDMA-assisted therapy, a novel treatment for PTSD with FDA breakthrough therapy designation, is on track for NDA submission in 2023 pending results of the confirmatory Phase 3 trial.

Therapy 52

Therapy Treatment Access Patients 52

Veriheal

AUGUST 9, 2023

Equally, 76% believed that addiction is preventable and treatable, underscoring the value of early intervention and treatment programs. Results showed that 58% of respondents were aware of naloxone, but only 35% reported that they would know where to access it in an emergency.

Education 98

Education Vaping Cannabis Consumption 98

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Schedule I controlled substances are the most restricted in terms of research, supply, and access, [13] and possession is criminalized.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. Using data from the Therapeutic Goods Administration (TGA) – Australia’s Special Access Scheme B, the researchers found the other two top reasons for prescriptions were pain and sleep disorders. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Veriheal

DECEMBER 27, 2022

The subjective nature of self-reported data can plague research. In an August 2022 study published by the Journal of the American Medical Association (JAMA) , psilocybin appears to be an effective tool for reducing problematic alcohol consumption. However, it does suggest a strong association between the two.

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

MARCH 9, 2022

“These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies.” Health Canada license renewal expands Numinus’ extensive list of permissible R&D activities.

Research and Development 52

Research and Development Therapy Access Medicine 52

Cannabis Law Report

JANUARY 17, 2022

VANCOUVER, BC / ACCESSWIRE / January 17, 2022 / Telescope Innovations Corp. (“ Telescope ” or the “ Company “) (CSE:TELI) announces that it has filed a Patent Cooperation Treaty (“ PCT “) patent application for its scalable manufacturing methods to produce psilocybin and related tryptamine compounds.

Research and Development 52

Research and Development Pharmaceutical Access Medicine 52

Cannabis Law Report

JULY 24, 2022

The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years [1]. The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 billion by 2029.

Research and Development 52

Research and Development Legalization Treatment Patients 52

Cannabis Law Report

MARCH 17, 2022

COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. 15 March 2022. The latest report presents data on Australia’s drug consumption for 12 substances.

Consumption 52

Consumption Programs Data Treatment 52

Cannabis Law Report

JANUARY 4, 2022

Medical marijuana treatment centers like Gold Leaf are the only businesses currently authorized to cultivate, process, and dispense low-THC cannabis and medical marijuana in Florida. Agrify brings data, science, and technology to its customers for unparalleled control over cultivation and extraction. BILLERICA, Mass., BILLERICA, Mass.,

Extraction 52

Extraction Cultivation Programs Data 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

AUGUST 5, 2022

Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment? Ketamine treatment for depression may be one of the biggest leaps forward in mental healthcare in decades.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

JANUARY 5, 2022

Young and Joyce also question the federal government’s motives, stating, “To be clear, we do not negate the benefit of traditional therapies, but question why the federal government continues to bar access to innovative, proven—and in many cases—safer alternatives.” Young’s Trail of Cannabis Reform.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules aim to promote social equity, safety and easy access to the cannabis marketplace while keeping local municipalities in control of how they want cannabis businesses to operate in their jurisdiction. –> Scroll to see full table data. Submission Fee.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Programs shall train students on how to proactively make psilocybin services accessible to people with disabilities. Group Psilocybin Facilitation (8 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 9, 2022

Of the cannabis-related tax revenue it collects, the state distributes 40% to public schools, 15% to law enforcement, and 25% to mental health and treatment programs. Regulated sales are scheduled to begin on May 1, 2022. Sales began in January 2022. Sales are expected to begin in 2022. Arizona (pop. Montana (pop.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

MAY 6, 2022

May 6, 2022. Generally, a CBD product seller is expected (or required by law) to provide customers with access to a “certificate of analysis” or “COA” associated with specific products, which COA confirms the levels of CBD in products and upon which customers can rely. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Veriheal

SEPTEMBER 14, 2021

The findings of a new study into cannabis use disorder (CUD) among veterans have been released by a team of researchers from Pennsylvania’s Center of Excellence in Substance Addiction Treatment and Education at the Corporal Michael J. Senators Voted to Broaden Medical Cannabis Access for Veterans . Crescenz VA Medical Center.

Consumption 97

Consumption Research and Development Treatment Programs 97

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. Published on November 30, 2021. 18 articles.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

FEBRUARY 28, 2022

Bronner’s, family-owned maker of the top-selling natural brand of soap in North America, has expanded its mental healthcare benefits to include Ketamine Assisted Therapy, as a first step in providing access to Psychedelic Assisted Therapy to employees to promote mental health. Bronner’s employees began on January 1, 2022.

Therapy 52

Therapy Treatment Research and Development Advocacy 52

Veriheal

AUGUST 31, 2021

His device not only provides an accessible option for cannabis users who are moving away from smoking but also opens up the opportunity for unique experiences with cannabis in the same way Starbucks revolutionized how people drink coffee. . Camille Elliott. School: Villanova University. Major/Program: Nursing. Guinevere Dorado.

Research and Development 116

Research and Development Supply Chain Programs Education 116

Cannabis Law Report

DECEMBER 15, 2021

In 2021, atai has achieved many major milestones, for example the promising phase 2a data for its schizophrenia drug RL-007 or the Phase 2b readout of Compass Pathways , of which atai owns 22.6% As we move into 2022, 10 milestones are anticipated to happen within the existing pipeline alone. 4) Digital & Data.

Research and Development 52

Research and Development Data History Patients 52

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. 7 The use of cannabis as a cancer treatment was popularized by Rick Simpson, a medical cannabis advocate. Use harm reduction techniques (i.e. Can cannabis fill this void?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. Review our compilation of cannabis trends for 2022 to stay up to date on the latest news in the cannabis industry and ensure you are prepared for the future.

Recreational 52

Recreational Data Cannabis DEA 52

Cannabis Law Report

SEPTEMBER 1, 2022

AUSTIN, Texas, August 31, 2022 –( BUSINESS WIRE )–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). 1 reason patients seek medical cannabis is to augment their pain management treatment.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52